Phase II Trial of Paclitaxel Poliglumex (CT-2103) in Pre- and Post-Menopausal Women on Hormonal Replacement Therapy with Non-Small Cell Lung Cancer
May 2011
in “
Journal of Clinical Oncology
”
Studysummary This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on ascopubs.org →